479 related items for PubMed ID: 23234782
1. [Risk factors for coronary artery lesions in children with Kawasaki disease].
Li Y, Wang XM, Liu YL, Shi K, Yang YF, Guo YH.
Zhongguo Dang Dai Er Ke Za Zhi; 2012 Dec; 14(12):938-41. PubMed ID: 23234782
[Abstract] [Full Text] [Related]
2. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM, Silverman ED, McCrindle BW, Yeung RS.
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[Abstract] [Full Text] [Related]
3. [Risk factors for coronary artery lesions secondary to Kawasaki disease in children].
Deng YC, Wang X, Tang XC, Huang CZ, Yang J, Mo LY.
Zhongguo Dang Dai Er Ke Za Zhi; 2015 Sep; 17(9):927-31. PubMed ID: 26412172
[Abstract] [Full Text] [Related]
4. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
[Abstract] [Full Text] [Related]
5. Characteristics of Kawasaki disease in older children.
Cai Z, Zuo R, Liu Y.
Clin Pediatr (Phila); 2011 Oct; 50(10):952-6. PubMed ID: 21628347
[Abstract] [Full Text] [Related]
6. [Clinical analysis of 942 cases of Kawasaki disease].
Zhang W, Li Q, Zhao XD, Tang XM, Wang XG, Wang M, Wu DQ, Ou Q, Yang XQ.
Zhonghua Er Ke Za Zhi; 2006 May; 44(5):324-8. PubMed ID: 16780705
[Abstract] [Full Text] [Related]
7. Infections and Kawasaki disease: implications for coronary artery outcome.
Benseler SM, McCrindle BW, Silverman ED, Tyrrell PN, Wong J, Yeung RS.
Pediatrics; 2005 Dec; 116(6):e760-6. PubMed ID: 16322132
[Abstract] [Full Text] [Related]
8. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
Qin LJ, Wang HW, Hu XF, Liu QJ, Shi H, Wei YX, Chen QJ, Cheng PX.
Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):891-5. PubMed ID: 17254453
[Abstract] [Full Text] [Related]
9. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease.
Kuo HC, Wang CL, Liang CD, Yu HR, Chen HH, Wang L, Yang KD.
J Microbiol Immunol Infect; 2007 Oct; 40(5):395-400. PubMed ID: 17932598
[Abstract] [Full Text] [Related]
10. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H.
Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
[Abstract] [Full Text] [Related]
11. Reevaluation of the efficacy of intravenous gammaglobulin in the prevention and treatment of coronary artery lesion in Kawasaki disease.
Qin L, Saumu MT, Wang H, Shi H, Hu X, Cheng P.
J Huazhong Univ Sci Technolog Med Sci; 2005 May; 25(3):348-50, 370. PubMed ID: 16201293
[Abstract] [Full Text] [Related]
12. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.
Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
[Abstract] [Full Text] [Related]
13. [Clinical features of recurrent Kawasaki disease in 20 children].
Zou LX, Gong FQ.
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Oct; 10(5):617-9. PubMed ID: 18947484
[Abstract] [Full Text] [Related]
14. Risk factors for coronary artery lesions in children with Kawasaki disease.
Duan J, Jiang H, Lu M.
Arch Argent Pediatr; 2020 Oct; 118(5):327-331. PubMed ID: 32924395
[Abstract] [Full Text] [Related]
15. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease.
Manlhiot C, Yeung RS, Chahal N, McCrindle BW.
Pediatr Allergy Immunol; 2010 May; 21(3):515-21. PubMed ID: 20546528
[Abstract] [Full Text] [Related]
16. Clinical relevance of the risk factors for coronary artery lesions in Kawasaki disease.
Weng KP, Hsieh KS, Huang SH, Ou SF, Ma CY, Ho TY, Lai CR, Ger LP.
Kaohsiung J Med Sci; 2012 Jan; 28(1):23-9. PubMed ID: 22226058
[Abstract] [Full Text] [Related]
17. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[Abstract] [Full Text] [Related]
18. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[Abstract] [Full Text] [Related]
19. N-terminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease.
Yoshimura K, Kimata T, Mine K, Uchiyama T, Tsuji S, Kaneko K.
J Pediatr; 2013 Jun; 162(6):1205-9. PubMed ID: 23290510
[Abstract] [Full Text] [Related]
20. Factors affecting the duration of coronary artery lesions in patients with the Kawasaki disease: a retrospective cohort study.
Zhang X, He Y, Shao Y, Hang B, Xu Z, Chu M.
Pediatr Rheumatol Online J; 2021 Jun 26; 19(1):96. PubMed ID: 34174872
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
